Skip Navigation


NDT Advance Access originally published online on July 28, 2008
Nephrology Dialysis Transplantation 2008 23(10):3056-3060; doi:10.1093/ndt/gfn429
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
23/10/3056    most recent
gfn429v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rietveld, A.
Right arrow Articles by Berden, J. H. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rietveld, A.
Right arrow Articles by Berden, J. H. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Renal replacement therapy in lupus nephritis

Anke Rietveld and Jo H. M. Berden

Division of Nephrology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Jo H. M. Berden, Division of Nephrology (464), Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Tel: +31-24-361-4761; Fax: +31-24-354-0022; E-mail: j.berden@nier.umcn.nl

Keywords: haemodialysis; lupus nephritis; peritoneal dialysis; renal transplantation

The first 150 words of the full text of this article appear below.



   Introduction
 
Recently, the therapeutic options for the treatment of lupus nephritis (LN) have increased by the promising results of treatment with mycophenolate mofetil (MMF), anti-CD20 and other biological medications. However, whether these treatments will reduce the ultimate development of end-stage renal failure (ESRF) is not known yet. Although compared to prednisone monotherapy, treatment with prednisone and cyclophosphamide or azathioprine reduces the cumulative incidence of ESRF in LN; still 20% of the patients develop ESRF [1]. In this editorial, we will review the results of the various forms of renal replacement therapy [i.e. haemodialysis, peritoneal dialysis and (pre-emptive) renal transplantation] in patients with ESRF due to LN.



   Haemodialysis
 
Initially, there was reluctance to dialyse lupus patients with ESRF because of the systemic nature of the disease and the (previous) use of immunosuppressives. In 1973, Coplon and colleagues documented that haemodialysis and renal transplantation in lupus patients had a favourable short-term prognosis, . . . [Full Text of this Article]

Peritoneal dialysis


   Renal transplantation
 
Pre-transplant screening
Cadaveric renal transplantation


   Living donor transplantation
 
Immunosuppressive therapy after renal transplantation
Recurrence of LN after renal transplantation
Lupus disease activity after renal transplantation


   Summary
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?